Get the Stockscreener App
77.08
0.72%
0.55
Apogee Therapeutics Inc stock is traded at $77.08, with a volume of 1.15M.
It is up +0.72% in the last 24 hours and up +22.16% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$76.53
Open:
$77.29
24h Volume:
1.15M
Relative Volume:
1.48
Market Cap:
$5.27B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-27.99
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+0.43%
1M Performance:
+22.16%
6M Performance:
+84.14%
1Y Performance:
+73.92%
1-Day Range:
$74.48
$78.11
1-Week Range:
$70.54
$78.11
52-Week Range:
$26.20
$78.11
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
77.08 | 5.23B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc. $APGE Shares Sold by Braidwell LP - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighHere's Why - MarketBeat
Apogee Therapeutics stock reaches all-time high of 77.21 USD - Investing.com India
Apogee Therapeutics stock reaches all-time high of 77.21 USD By Investing.com - Investing.com Canada
Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE - MarketBeat
Deutsche Bank Initiates Apogee Therapeutics at Buy With $103 Price Target - marketscreener.com
Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank - Investing.com
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank By Investing.com - Investing.com India
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Yahoo Finance
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock - MarketBeat
Carl Dambkowski Sells 10,900 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Apogee Therapeutics CMO sells $817k in stock By Investing.com - Investing.com Australia
Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CEO Henderson sells $3.0 million in stock By Investing.com - Investing.com Canada
Apogee Therapeutics CMO sells $817k in stock - Investing.com India
Apogee Therapeutics CFO Henderson sells $112,500 in shares By Investing.com - Investing.com UK
CFO Henderson Sells 1,500 ($112.5K) Of Apogee Therapeutics Inc [APGE] - TradingView
CEO Henderson Sells 40,000 ($3M) Of Apogee Therapeutics Inc [APGE] - TradingView
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighHere's What Happened - MarketBeat
Prudential Financial Inc. Has $2.99 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits all-time high at 73.99 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 73.99 USD - Investing.com
Transcript : Apogee Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 09 - marketscreener.com
(APGE) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
How Apogee Therapeutics Inc. stock benefits from global expansionWeekly Profit Recap & Long-Term Growth Portfolio Plans - BỘ NỘI VỤ
Henderson, Apogee Therapeutics CFO, sells $105k in stock By Investing.com - Investing.com Canada
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView
CFO Henderson Sells 1,500 ($105K) Of Apogee Therapeutics Inc [APGE] - TradingView
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - MSN
Franklin Resources Inc. Lowers Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Geode Capital Management LLC Has $33.99 Million Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Inc. $APGE Position Boosted by Jefferies Financial Group Inc. - MarketBeat
Is Apogee Therapeutics Inc a good long term investmentInsider Trading Compliance & High Yield Trading Alerts - earlytimes.in
Responsive Playbooks and the APGE Inflection - news.stocktradersdaily.com
Apogee Therapeutics (NASDAQ:APGE) Hits New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics stock hits 52-week high at $67.66 By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits 52-week high at $67.66 - Investing.com
Is Apogee Therapeutics Inc. stock recession proofWeekly Stock Summary & High Conviction Buy Zone Picks - newser.com
How to track smart money flows in Apogee Therapeutics Inc.2025 Price Momentum & Daily Market Momentum Tracking - newser.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):